Literature DB >> 27138845

Functionalizing Ascl1 with Novel Intracellular Protein Delivery Technology for Promoting Neuronal Differentiation of Human Induced Pluripotent Stem Cells.

Meghan Robinson1, Parv Chapani2, Tara Styan1, Ranjani Vaidyanathan3, Stephanie Michelle Willerth4,5,6.   

Abstract

Pluripotent stem cells can become any cell type found in the body. Accordingly, one of the major challenges when working with pluripotent stem cells is producing a highly homogenous population of differentiated cells, which can then be used for downstream applications such as cell therapies or drug screening. The transcription factor Ascl1 plays a key role in neural development and previous work has shown that Ascl1 overexpression using viral vectors can reprogram fibroblasts directly into neurons. Here we report on how a recombinant version of the Ascl1 protein functionalized with intracellular protein delivery technology (Ascl1-IPTD) can be used to rapidly differentiate human induced pluripotent stem cells (hiPSCs) into neurons. We first evaluated a range of Ascl1-IPTD concentrations to determine the most effective amount for generating neurons from hiPSCs cultured in serum free media. Next, we looked at the frequency of Ascl1-IPTD supplementation in the media on differentiation and found that one time supplementation is sufficient enough to trigger the neural differentiation process. Ascl1-IPTD was efficiently taken up by the hiPSCs and enabled rapid differentiation into TUJ1-positive and NeuN-positive populations with neuronal morphology after 8 days. After 12 days of culture, hiPSC-derived neurons produced by Ascl1-IPTD treatment exhibited greater neurite length and higher numbers of branch points compared to neurons derived using a standard neural progenitor differentiation protocol. This work validates Ascl1-IPTD as a powerful tool for engineering neural tissue from pluripotent stem cells.

Entities:  

Keywords:  Drug delivery; Intracellular targeting; Neurite extension; Neuroscience; Proteins; Stem cells

Mesh:

Substances:

Year:  2016        PMID: 27138845     DOI: 10.1007/s12015-016-9655-7

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  30 in total

1.  Rapid Conversion of Fibroblasts into Functional Forebrain GABAergic Interneurons by Direct Genetic Reprogramming.

Authors:  Gaia Colasante; Gabriele Lignani; Alicia Rubio; Lucian Medrihan; Latefa Yekhlef; Alessandro Sessa; Luca Massimino; Serena G Giannelli; Silvio Sacchetti; Massimiliano Caiazzo; Damiana Leo; Dimitra Alexopoulou; Maria Teresa Dell'Anno; Ernesto Ciabatti; Marta Orlando; Michele Studer; Andreas Dahl; Raul R Gainetdinov; Stefano Taverna; Fabio Benfenati; Vania Broccoli
Journal:  Cell Stem Cell       Date:  2015-10-29       Impact factor: 24.633

Review 2.  Cell-based therapy approaches: the hope for incurable diseases.

Authors:  Ella Buzhor; Lucy Leshansky; Jacob Blumenthal; Hila Barash; David Warshawsky; Yaron Mazor; Ronit Shtrichman
Journal:  Regen Med       Date:  2014       Impact factor: 3.806

3.  Transgenic expression of the proneural transcription factor Ascl1 in Müller glia stimulates retinal regeneration in young mice.

Authors:  Yumi Ueki; Matthew S Wilken; Kristen E Cox; Laura Chipman; Nikolas Jorstad; Kristen Sternhagen; Milesa Simic; Kristy Ullom; Masato Nakafuku; Thomas A Reh
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-19       Impact factor: 11.205

Review 4.  Vectorology and factor delivery in induced pluripotent stem cell reprogramming.

Authors:  Kejin Hu
Journal:  Stem Cells Dev       Date:  2014-04-16       Impact factor: 3.272

5.  Embryonic stem cell lines derived from human blastocysts.

Authors:  J A Thomson; J Itskovitz-Eldor; S S Shapiro; M A Waknitz; J J Swiergiel; V S Marshall; J M Jones
Journal:  Science       Date:  1998-11-06       Impact factor: 47.728

6.  Mash1 regulates neurogenesis in the ventral telencephalon.

Authors:  S Casarosa; C Fode; F Guillemot
Journal:  Development       Date:  1999-02       Impact factor: 6.868

Review 7.  Neural tissue engineering using embryonic and induced pluripotent stem cells.

Authors:  Stephanie M Willerth
Journal:  Stem Cell Res Ther       Date:  2011-04-15       Impact factor: 6.832

Review 8.  Transcriptional control of vertebrate neurogenesis by the proneural factor Ascl1.

Authors:  Francisca F Vasconcelos; Diogo S Castro
Journal:  Front Cell Neurosci       Date:  2014-12-02       Impact factor: 5.505

9.  Reprogramming somatic cells to cells with neuronal characteristics by defined medium both in vitro and in vivo.

Authors:  Yiping Guo; Yixin Zhang; Yuan Li; Songwei He; Chengqian Feng; Xiang Li; Lilong Lin; Lin Guo; Haitao Wang; Chunhua Liu; Yi Zheng; Chuanming Luo; Qiang Liu; Fuhui Wang; Hao Sun; Lining Liang; Lingyu Li; Huanxing Su; Jiekai Chen; Duanqing Pei; Hui Zheng
Journal:  Cell Regen       Date:  2015-12-30

10.  Identification of transcription factors for lineage-specific ESC differentiation.

Authors:  Kohei Yamamizu; Yulan Piao; Alexei A Sharov; Veronika Zsiros; Hong Yu; Kazu Nakazawa; David Schlessinger; Minoru S H Ko
Journal:  Stem Cell Reports       Date:  2013-11-27       Impact factor: 7.765

View more
  8 in total

1.  ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer.

Authors:  Shaghayegh Nouruzi; Dwaipayan Ganguli; Nakisa Tabrizian; Maxim Kobelev; Olena Sivak; Takeshi Namekawa; Daksh Thaper; Sylvan C Baca; Matthew L Freedman; Adeleke Aguda; Alastair Davies; Amina Zoubeidi
Journal:  Nat Commun       Date:  2022-04-27       Impact factor: 17.694

Review 2.  Targeting NMDA receptors in neuropsychiatric disorders by drug screening on human neurons derived from pluripotent stem cells.

Authors:  Wenbo Zhang; P Joel Ross; James Ellis; Michael W Salter
Journal:  Transl Psychiatry       Date:  2022-06-09       Impact factor: 7.989

3.  Engineering personalized neural tissue using functionalized transcription factors.

Authors:  Stephanie M Willerth
Journal:  Neural Regen Res       Date:  2016-10       Impact factor: 5.135

4.  Rapid DNA replication origin licensing protects stem cell pluripotency.

Authors:  Jacob Peter Matson; Raluca Dumitru; Philip Coryell; Ryan M Baxley; Weili Chen; Kirk Twaroski; Beau R Webber; Jakub Tolar; Anja-Katrin Bielinsky; Jeremy E Purvis; Jeanette Gowen Cook
Journal:  Elife       Date:  2017-11-17       Impact factor: 8.140

Review 5.  The Potential of Targeting Brain Pathology with Ascl1/Mash1.

Authors:  Bor Luen Tang
Journal:  Cells       Date:  2017-08-23       Impact factor: 6.600

6.  Comparison of Four Protocols to Generate Chondrocyte-Like Cells from Human Induced Pluripotent Stem Cells (hiPSCs).

Authors:  Wiktoria Maria Suchorska; Ewelina Augustyniak; Magdalena Richter; Tomasz Trzeciak
Journal:  Stem Cell Rev Rep       Date:  2017-04       Impact factor: 5.739

7.  Transdifferentiating Astrocytes Into Neurons Using ASCL1 Functionalized With a Novel Intracellular Protein Delivery Technology.

Authors:  Meghan Robinson; Ian Fraser; Emily McKee; Kali Scheck; Lillian Chang; Stephanie M Willerth
Journal:  Front Bioeng Biotechnol       Date:  2018-11-21

Review 8.  Evolving principles underlying neural lineage conversion and their relevance for biomedical translation.

Authors:  Lea Jessica Flitsch; Oliver Brüstle
Journal:  F1000Res       Date:  2019-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.